december 2023

ASH 2023: CAPTIVATE Study – Ibrutinib-Venetoclax for CLL/SLL

The CAPTIVATE study’s latest findings offer new hope for CLL/SLL patients with the oral ibrutinib-venetoclax, demonstrating lasting remissions and promising retreatment outcomes.

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Få adgang
Hvis du allerede har en profil: Log ind

Relateret indhold

CLL: Needs At Least 10 Years of Follow-Up for Clinical Trials

november 2024 / BestPractice Nordic

EHA24 CLL

Promising Efficacy of Zanubrutinib + Venetoclax Treatment in Patients with High-Risk Treatment-Naïve CLL/SLL with Del 17p and/or TP53 Mutation

juni 2024 / Paolo Ghia

EHA24 CLL 02:42

Impact of First-Year Dose Modifications of Acalabrutinib in Patients with CLL

juni 2024 / Alessandra Tedeschi

EHA24 CLL 01:52

Drug Sensitivity Screening to Guide Clinical Decisions for Hematologic Cancers

januar 2024 / Sigrid S. Skånland

AML CLL

Potential for Targeted and Immune-Facing Therapies for Patients with CNS Lymphoma

december 2023 / Jason Westin

ASH23 Lymfom 01:08

MRD Status in NPM1 Mutated AML Should Be a Part of the Selection of Patients for Transplant in First Remission

december 2023 / Jad Othman

ASH23 AML 03:32

Chemotherapy Might Not Be Needed in Frontline Treatment of Patients with Large B-Cell Lymphoma

december 2023 / Jason Westin

ASH23 B-celle lymfom 2:05

Undiagnosed and Unrecognized Patients with a High Bleeding Score

december 2023 / Eva Birgitte Leinøe

ASH23 03:43

A Potential New Standard of Care for Transplant-Eligible Patients with Multiple Myeloma

december 2023 / Pieter Sonneveld

ASH23 Myelomatose 05:04

Brænder du for at skrive?

Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk

Send mail til redaktionen